Skip to main content
Erschienen in: Tumor Biology 9/2015

01.09.2015 | Research Article

MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1

verfasst von: Jun Deng, Wan Lei, Xiaojun Xiang, Ling Zhang, Feng Yu, Jun Chen, Miao Feng, Jianping Xiong

Erschienen in: Tumor Biology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidence indicates that microRNA (miR)-506 plays a vital role in tumorigenesis; however, the role of miR-506 in gastric cancer (GC) is unclear and needs further investigation. In the present study, we showed that the decrease in the expression of miR-506 is associated with tumor size, pathological tumor node metastasis (TNM) stage, and lymph node metastasis in 63 GC patient tumors. We found that patients with lower expression of miR-506 had a poor prognosis than that with the patients with high expression of miR-506. Notably, the ectopic expression of miR-506 was sufficient to inhibit cell proliferation, invasion, and epithelial-mesenchymal transition in the GC cells. Moreover, results from luciferase reporter assays identified miR-506 as a direct regulator of Yes-associated protein 1 (Yap1). Reintroduction of Yap1 rescues miR-506-induced effects on SGC-7901 cell proliferation and invasion. This function of miR-506/Yap1 axis is clinically significant, as the level of miR-506 is inversely correlated with Yap1 mRNA expression in matched tissues. Thus, our study demonstrates that miR-506 may act as a tumor suppressor in GC and that the miR-506/Yap1 axis may help us better understand the molecular mechanisms of GC progression.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.
2.
Zurück zum Zitat Tong F, Cao P, Yin Y, Xia S, Lai R, Liu S. Micrornas in gastric cancer: from benchtop to bedside. Dig Dis Sci. 2014;59:24–30.CrossRefPubMed Tong F, Cao P, Yin Y, Xia S, Lai R, Liu S. Micrornas in gastric cancer: from benchtop to bedside. Dig Dis Sci. 2014;59:24–30.CrossRefPubMed
4.
Zurück zum Zitat Han TS, Hur K, Xu G, Choi B, Okugawa Y, Toiyama Y, et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut. 2015;64:203–14.CrossRefPubMed Han TS, Hur K, Xu G, Choi B, Okugawa Y, Toiyama Y, et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut. 2015;64:203–14.CrossRefPubMed
5.
Zurück zum Zitat Xia J, Wu Z, Yu C, He W, Zheng H, He Y, et al. MiR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 2012;227:470–80.CrossRefPubMed Xia J, Wu Z, Yu C, He W, Zheng H, He Y, et al. MiR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 2012;227:470–80.CrossRefPubMed
6.
Zurück zum Zitat Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. MiR-137 is frequently down-regulated in gastric cancer and is a negative regulator of CDC42. Dig Dis Sci. 2011;56:2009–16.CrossRefPubMed Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. MiR-137 is frequently down-regulated in gastric cancer and is a negative regulator of CDC42. Dig Dis Sci. 2011;56:2009–16.CrossRefPubMed
7.
Zurück zum Zitat Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 2011;141:2076–87.CrossRefPubMed Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 2011;141:2076–87.CrossRefPubMed
8.
Zurück zum Zitat Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. MiR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–8.CrossRefPubMed Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. MiR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–8.CrossRefPubMed
9.
Zurück zum Zitat Li F, Liu B, Gao Y, Liu Y, Xu Y, Tong W, et al. Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett. 2014;588:538–44.CrossRefPubMed Li F, Liu B, Gao Y, Liu Y, Xu Y, Tong W, et al. Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett. 2014;588:538–44.CrossRefPubMed
10.
Zurück zum Zitat Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, et al. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-kappaB signaling. J Transl Med. 2014;12:33.CrossRefPubMedPubMedCentral Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, et al. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-kappaB signaling. J Transl Med. 2014;12:33.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li H, et al. MicroRNA-296-5p increases proliferation in gastric cancer through repression of caudal-related homeobox 1. Oncogene. 2014;33:783–93.CrossRefPubMed Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li H, et al. MicroRNA-296-5p increases proliferation in gastric cancer through repression of caudal-related homeobox 1. Oncogene. 2014;33:783–93.CrossRefPubMed
12.
Zurück zum Zitat Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:186–99.CrossRefPubMedPubMedCentral Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:186–99.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014;233:308–18.CrossRefPubMedPubMedCentral Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014;233:308–18.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, et al. MiR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor GLI3 in human cervical cancer. Oncogene. 2015;34:717–25.CrossRefPubMed Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, et al. MiR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor GLI3 in human cervical cancer. Oncogene. 2015;34:717–25.CrossRefPubMed
15.
Zurück zum Zitat Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185–97.CrossRefPubMedPubMedCentral Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185–97.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25:166–80.CrossRefPubMed Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25:166–80.CrossRefPubMed
17.
Zurück zum Zitat Song M, Cheong JH, Kim H, Noh SH, Kim H. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res. 2012;32:3827–34.PubMed Song M, Cheong JH, Kim H, Noh SH, Kim H. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res. 2012;32:3827–34.PubMed
18.
Zurück zum Zitat Johnson R, Halder G. The two faces of hippo: targeting the hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13:63–79.CrossRefPubMed Johnson R, Halder G. The two faces of hippo: targeting the hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13:63–79.CrossRefPubMed
19.
Zurück zum Zitat Ma Y, Yang Y, Wang F, Wei Q, Qin H: Hippo-YAP signaling pathway: a new paradigm for cancer therapy. Int J Cancer J Int Du Cancer. 2014. Ma Y, Yang Y, Wang F, Wei Q, Qin H: Hippo-YAP signaling pathway: a new paradigm for cancer therapy. Int J Cancer J Int Du Cancer. 2014.
20.
Zurück zum Zitat Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 2008;13:188–92.CrossRefPubMed Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 2008;13:188–92.CrossRefPubMed
21.
Zurück zum Zitat Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2012;31:1558–70.CrossRefPubMed Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2012;31:1558–70.CrossRefPubMed
22.
Zurück zum Zitat Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM, Xiao SD, et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011;585:3560–8.CrossRefPubMed Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM, Xiao SD, et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011;585:3560–8.CrossRefPubMed
23.
Zurück zum Zitat Wang Y, Cui M, Sun BD, Liu FB, Zhang XD, Ye LH. Mir-506 suppresses proliferation of hepatoma cells through targeting yap mRNA 3′ UTR. Acta Pharmacol Sin. 2014;35:1207–14.CrossRefPubMedPubMedCentral Wang Y, Cui M, Sun BD, Liu FB, Zhang XD, Ye LH. Mir-506 suppresses proliferation of hepatoma cells through targeting yap mRNA 3′ UTR. Acta Pharmacol Sin. 2014;35:1207–14.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Lim B, Park JL, Kim HJ, Park YK, Kim JH, Sohn HA, et al. Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer. Carcinogenesis. 2014;35:1020–7.CrossRefPubMed Lim B, Park JL, Kim HJ, Park YK, Kim JH, Sohn HA, et al. Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer. Carcinogenesis. 2014;35:1020–7.CrossRefPubMed
25.
Zurück zum Zitat Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS, et al. Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer. 2011;10:122.CrossRefPubMedPubMedCentral Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS, et al. Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer. 2011;10:122.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Maeta N, Osaki M, Shomori K, Inaba A, Kidani K, Ikeguchi M, et al. CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology. 2007;73:118–26.CrossRefPubMed Maeta N, Osaki M, Shomori K, Inaba A, Kidani K, Ikeguchi M, et al. CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology. 2007;73:118–26.CrossRefPubMed
27.
Zurück zum Zitat Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57.CrossRefPubMed Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57.CrossRefPubMed
28.
Zurück zum Zitat Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP, Xue CH, et al. Effects of the hippo signaling pathway in human gastric cancer. Asian Pacif J Cancer Prev: APJCP. 2013;14:5199–205.CrossRef Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP, Xue CH, et al. Effects of the hippo signaling pathway in human gastric cancer. Asian Pacif J Cancer Prev: APJCP. 2013;14:5199–205.CrossRef
29.
Zurück zum Zitat Tsai BP, Hoverter NP, Waterman ML. Blending hippo and WNT: sharing messengers and regulation. Cell. 2012;151:1401–3.CrossRefPubMed Tsai BP, Hoverter NP, Waterman ML. Blending hippo and WNT: sharing messengers and regulation. Cell. 2012;151:1401–3.CrossRefPubMed
30.
Zurück zum Zitat Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates jagged-1 and activates the notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144:1530–42.CrossRefPubMedPubMedCentral Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates jagged-1 and activates the notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144:1530–42.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol. 2012;14:1322–9.CrossRefPubMedPubMedCentral Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol. 2012;14:1322–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1
verfasst von
Jun Deng
Wan Lei
Xiaojun Xiang
Ling Zhang
Feng Yu
Jun Chen
Miao Feng
Jianping Xiong
Publikationsdatum
01.09.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 9/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3364-8

Weitere Artikel der Ausgabe 9/2015

Tumor Biology 9/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.